Alnylam Pharmaceuticals, Inc. ALNY
Alnylam Pharmaceuticals, Inc. is a leading biotechnology company that specializes in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company operates as a fully integrated commercial-stage biopharmaceutical firm, focusing on genetically defined diseases with high unmet medical needs. Alnylam's business model involves extensive research and development to create novel medicines, followed by commercialization either through direct sales of its own products or through strategic collaborations and partnerships with other pharmaceutical companies. The company serves patients globally through its commercial products and has a robust pipeline of investigational therapies in various stages of clinical development. Alnylam's operations span research facilities, manufacturing sites, and commercial offices across multiple countries including the United States, Switzerland, the United Kingdom, the Netherlands, and Japan, enabling it to address both domestic and international markets effectively.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.